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ABSTRACT 
Objectives: To study the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients 
with heart failure and reduced ejection fraction. 
 
Background: Many patients with type 2 diabetes mellitus have heart failure and it is important 
to know about the safety of new treatments for diabetes in these individuals. 
 
Methods: Patients aged 18 to 85 years with type 2 diabetes and heart failure (New York Heart 
Association functional class I to III and left ventricular ejection fraction [LVEF] < 0.40) were 
randomized to 52 weeks treatment with vildagliptin 50 mg twice daily (50 mg once daily if 
treated with a sulfonylurea) or matching placebo.  The primary endpoint was between-
treatment change from baseline in echocardiographic LVEF using a non-inferiority margin of -
3.5%.   
 
Findings:  254 patients were randomly assigned to vildagliptin (n=128) or placebo (n=126).  
Baseline LVEF was 30.6 (SD 6.8)% in the vildagliptin group and 29.6 (7.7)% in the placebo 
group.  The adjusted mean change in LVEF was 4.95 (SE 1.25)% in vildagliptin treated 
patients and 4.33 (1.23)% in placebo treated patients – a difference of 0.62 (95% CI -2.21, 
3.44); p=0.667.  This difference met the predefined non-inferiority margin of -3.5%. Left 
ventricular end-diastolic and end-systolic volumes increased more in the vildagliptin group: by 
17.1 (4.6, 29.5) ml; p=0.007 and 9.4 (-0.49, 19.4) ml; p=0.062, respectively.  Decrease in 
haemoglobin A1c from baseline to 16 weeks, the main secondary endpoint, was greater in the 
vildagliptin group: -0.62 (-0.93, -0.30); p<0.001. 
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Conclusions:  Compared with placebo, vildagliptin had no major effect on LVEF but did lead 
to an increase in left ventricular volumes, the cause and clinical significance of which is 
unknown. More evidence is needed regarding the safety of dipeptidyl peptidase-4 inhibitors in 
patients with heart failure and left ventricular systolic dysfunction. 
 
Key words: Diabetes, Heart Failure. 
 
Trial registration: ClinicalTrials.gov NCT00894868 
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INTRODUCTION 
Type 2 diabetes is common in patients with heart failure with reported prevalences of between 
25 and 40 per cent in trials and registries.
1-5
  Heart failure patients with diabetes have worse 
symptoms, greater functional limitation and higher rates of hospitalization and death than 
heart failure patients without diabetes.
1-5
  The safety of established treatments for diabetes in 
patients with heart failure is uncertain.  While there are no known concerns about 
sulfonylureas and insulin, it has been thought that metformin might increase the risk of lactic 
acidosis although this has never been demonstrated.
6,7
 Thiazolidinediones increase the risk of 
patients with diabetes developing heart failure.
8,9
  Thiazolidinediones also increase the risk of 
worsening of heart failure in patients with that condition.
10,11
 
 
Consequently, it is important that the safety of new treatments for diabetes is studied in 
patients with heart failure.  One group of new treatments are the dipeptidyl peptidase-4 (DPP-
4) inhibitors which block the degradation of endogenous glucagon-like peptide-1 (GLP-1) and 
glucose dependent insulinotropic polypeptide (GIP) which stimulate insulin secretion in a 
glucose-dependent manner, suppress glucagon release and slow gastric emptying.
12-14
 Three 
recent large randomized controlled trials have reported conflicting evidence about the risk of 
heart failure with different agents in this class.
 15-17 
None, however, characterized patients with 
heart failure at baseline or those developing heart failure during follow-up. Further, none 
examined the effect of a DPP-4 inhibitor on left ventricular ventricular function. Here we 
report a study of the effects of the DPP-4 inhibitor vildagliptin in patients with heart failure 
and reduced ejection fraction (HF-REF).
18,19
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METHODS 
The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD) was a prospective, 
randomized, double-blind, parallel-group trial comparing vildagliptin and placebo, added to 
standard therapy, for 52 weeks in patients with type 2 diabetes and heart failure with a reduced 
ejection fraction.  An ethics committee approved the trial at each site and patients provided 
written informed consent.  Patient safety was reviewed by an independent committee 
throughout the trial and cardiovascular, hepatic and cutaneous (including suspected 
angioedema) adverse events were adjudicated by independent and masked committees.  All 
echocardiographic analyses were carried out by blinded assessors in a core laboratory 
(Perceptive Informatics Inc., a subsidiary of Parexel International - see below).  The study 
results were analysed by Novartis and confirmed by an independent statistician at the 
University of Glasgow (J.L.).  
 
Participants 
In brief, men and women aged between 18 and 85 years with type 2 diabetes (hemoglobin A1c 
6.5% - 10.0%), body mass index 22 – 42 kg/m2, heart failure with a reduced ejection fraction 
(< 40%) and inNew York Heart Association (NYHA) functional class I to III were eligible.  
The key exclusion criteria were NYHA functional class IV, a fasting plasma glucose of ≥15 
mmol/1, thiazolidinedione or incretin therapy, a recent cardiovascular event or procedure, 
creatinine clearance <30 ml/min and liver disease or elevated transaminases or bilirubin. 
 
Randomization and masking 
Eligible patients were randomly assigned in a 1:1 ratio according to a central randomization 
scheme, stratified by NYHA class, to one of two treatment groups: vildagliptin 50 mg twice 
daily (50 mg once daily if concomitant treatment with a sulfonylurea) or placebo.  
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Randomization was conducted using an interactive voice response system.  Vildagliptin and 
placebo were identical in packaging, labelling, appearance and schedule of administration.  
 
Procedures 
From 04 May 2009 (Figure 1), subjects who met the inclusion/exclusion criteria (including 
echocardiographic criteria) at the screening visit entered a 2 to 4 week run-in period during 
which the individuals continued their usual diet, exercise regimen and drug therapy for 
diabetes (if taking drug therapy).  Patients completing this period returned for baseline 
assessment including measurement of B type natriuretic peptide (BNP) and were then 
randomized to vildagliptin or placebo as described above.  Patients were reviewed every 4 
weeks up to week 24 and every 8 weeks thereafter (diabetes “rescue” therapy could be used 
from week 16 onwards). Repeat BNP measurements and echocardiography were performed at 
24 and 52 weeks.  Patients permanently stopping treatment before 52 weeks were asked to 
return for a final assessment, including an echocardiogram and BNP measurement.  NYHA 
class, dyspnea and edema were evaluated at baseline and at each of the follow-up visits, as 
was blood chemistry (including hemoglobin A1c) and hematological measurements.   
 
Echocardiography 
Each echocardiogram was analyzed by a minimum of 2 qualified echocardiographers blinded 
to treatment assignment and according to a pre-specified protocol.  The Simpson biplane 
method of discs was used to calculate LVEF.
20 
 
B-type natriuretic peptide (BNP) 
BNP was measured using a triage Beckman Coulter Immunoassay (Covance Central 
Laboratory services). 
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Study objectives 
This was a safety study.  The primary objective was to show that vildagliptin was at least non-
inferior to placebo with respect to change in LVEF from baseline to end of study.  
Recognizing that not all patients would complete the planned maximum of 52 weeks of 
treatment and that an effect of drugs on left ventricular remodelling may be apparent within 6 
months, the original protocol was altered during the trial (but before any results were known) 
to define the primary analysis of LVEF to include any patient who had at least one follow-up 
echocardiogram recorded 22 weeks or more after randomization.  The key secondary endpoint 
was change in hemoglobin A1c from baseline to 16 weeks (with censoring for use of rescue 
therapy before that time-point). 
 
Safety assessments 
In addition to conventional adverse event reporting, specific safety assessments were made 
including assessment of NYHA class and breathlessness and edema at each study visit and 
adjudication of suspected worsening heart failure symptoms (see Appendix Table 1), and 
possible cardiovascular, liver and cutaneous events, as well as deaths, by the adjudication 
committees described above. 
 
Statistical analysis 
The study sample size was calculated based upon 90% power and a one-sided significance 
level of 0.025 to declare non-inferiority of vildagliptin, compared with placebo, for the effect 
of treatment of LVEF, using a margin of -3.5% and an expected difference between the two 
treatments of 0%.  The choice of the non-inferiority margin was based on clinical importance 
and prior use.
10
  The calculation was performed using nQuery Advisor version 5.0 and based 
on a LVEF standard deviation (SD) of 7% (derived from prior trials).  We calculated that a 
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total of 172 patients with at least one LVEF measurement after randomization were required.  
The sample-size was inflated to 246 patients to allow for approximately 30% of patients not 
having a LVEF measurement after randomization.  An analysis of co-variance model 
(ANCOVA) was fitted including terms for treatment, baseline LVEF, NYHA class and region.  
The least-square mean (LSM, “adjusted mean”) change from baseline in LVEF was calculated 
for each treatment group and the difference in LSM between the two treatment groups, and the 
two-sided 95% confidence interval (CI), were obtained from this model.  
 
An ANCOVA model fitted with terms for treatment, baseline haemoglobin A1c and region 
was used to analyse LSM change in hemoglobin A1c.  Other exploratory variables were 
analysed in a similar way with appropriate transformations if the normality assumption was 
questionable. The statistical software used was SAS® (Version 9.2). 
  
 RESULTS 
Baseline characteristics and treatment 
A total of 254 patients were randomized at 67 sites in 15 countries.  Their mean age was 63 
years and 77% were male.  Other key demographic characteristics, medical history and 
treatment at baseline are shown in Table 1.  The first patient visit was 04 May 2009 and the last 
patient visit was 13 August 2012. Overall, patients had a mean duration of diabetes of 9.3 years 
(median 6.8 years) and the mean hemoglobin A1c at baseline was 7.8% per cent; 34% of 
patients were treated with metformin and the same proportion with insulin, either as 
monotherapy or in combination with other glucose lowering agents.  The median duration of 
heart failure was 3.3 years, mean left ventricular ejection fraction was 30%, median BNP was 
231 pg/ml and most patients were in NYHA functional class II (53%) or III (37%); 48% of 
patients had a history of hospital admission for heart failure.  More than 90% of patients were 
treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, 78% 
with a beta-blocker and 42% with a mineralocorticoid receptor antagonist. Baseline 
characteristics between treatment groups were well balanced with exception of more patients in 
the vildagliptin treatment group having a history of smoking, prior hospitalization for heart 
failure, or chronic obstructive pulmonary disease. 
 
Follow-up and adherence 
Overall, 101 patients (79%) assigned to vildagliptin and 100 patients (79%) assigned to 
placebo completed the 52 week follow-up as planned (Figure 2).  There were 11 deaths (8.6%) 
in the vildagliptin group and 4 deaths (3.2%) in the placebo group.  Other reasons for not 
completing follow-up were adverse events (5 vildagliptin versus 4 placebo), withdrawal of 
consent (3 versus 10), protocol violation (3 versus 2), loss-to-follow-up (2 versus 2), 
unsatisfactory therapeutic effect (2 versus 1) and administrative problems (1 versus 3).  
 Overall, 16 patients (12.5%) assigned to vildagliptin and 22 patients (17.4%) assigned to 
placebo discontinued study drug early for reasons other than death. 
Primary endpoint: change in LVEF 
LVEF was matched between treatment groups at baseline (Table 2).  The intention to treat 
analysis is shown in Figure 2.  The pre-specified primary analysis (patients with a baseline and 
follow-up measurement of LVEF ≥22 weeks) included 89 patients assigned to vildagliptin 
(mean baseline LVEF 30.5 ± SE 0.67%) and 90 assigned to placebo (29.8 ± SE 0.78%).  The 
adjusted mean change in LVEF was 4.95 (± SE 1.25)% in the vildagliptin group and 4.33 (± 
SE 1.23)% in the placebo group;  a difference of 0.62  (95% confidence interval -2.21, 3.44; 
p=0.667).  This difference met the predefined non-inferiority criterion of -3.5% at p=0.025.  
Analysis of the patients (88 vildagliptin, 89 placebo) with a 48 week follow-up measurement of 
LVEF gave almost identical findings (see sensitivity analyses Appendix Table A2). 
 
Other echocardiographic findings 
Changes in left ventricular volumes are shown in Table 2 and Figure 3.  Left ventricular end-
diastolic volume increased significantly with vildagliptin compared with placebo and there was 
a trend in the same direction for end-systolic volume which was of borderline statistical 
significance (6 and 12 month volumes are shown in Appendix Table A3).  There was a 
significant increase in stroke volume but no change in left ventricular wall thickness or mass. 
 
Secondary endpoint: change in hemoglobin A1c 
The adjusted mean change from baseline to rescue-censored week 16 haemoglobin A1c was -
0.45 (± SE0.12)% in the vildagliptin group and 0.17 (±SE 0.12)% in the placebo group, with an 
adjusted mean difference (vildagliptin – placebo) of -0.62 (95% CI -0.03, -0.30)%; p<0.001.  
The difference at week 52 was -0.36 (95% CI -0.71, -0.02)%; p=0.040. 
  
 Change in B-type natriuretic peptide 
Baseline geometric mean BNP values for those with an end of study measurement were 227 
pg/ml in patients assigned to vildagliptin and 214 pg/ml in those assigned to placebo.  A 
reduction in geometric mean BNP values from baseline was observed in both treatment groups: 
ratio of 52 weeks/baseline: 0.72 (95% CI 0.56, 0.93) in the vildagliptin group (n=75) and 0.86 
(0.67, 1.12) in the placebo group (n=81).  The ratio of ratios (vildagliptin/placebo) was 0.84 
(0.62, 1.14), p=0.252. 
 
Other measures of heart failure status 
Changes in dyspnea and edema from baseline over the course of the study were small and did 
not differ between treatment groups.  There was no difference in change in NYHA class 
distribution between the two treatment groups and the proportion of patients with an increase in 
heart failure medication during the study was 26.6% in the vildagliptin group and 24% in the 
placebo group (p=0.640). Specifically, the proportion of patients taking loop diuretics at 
baseline was 64.8% and 65.9% of patients in the vildagliptin and the placebo groups, 
respectively, and increased during the study to 71.1% and 72.2%, respectively. Worsening 
heart failure (including hospitalisation for heart failure) was confirmed by the endpoint 
committee in 23 patients (18.0%) in the vildagliptin group and 22 patients (17.6%) in the 
placebo group; the number of episodes of worsening was 39 versus 33, respectively [Appendix 
Table A4].  Hospital admissions for heart failure were reported in 13 patients (10.2%) in the 
vildagliptin group and 10 patients (8.0%) in the placebo group (p=0.552). 
 
Other adjudicated cardiovascular events, hepatic events and deaths 
Overall, 19 vildagliptin treated patients (14.8%) and 14 placebo patients (11.2%) were admitted 
to hospital for a cardiovascular cause.  In addition to heart failure (see above), these included 
acute coronary syndrome (6.3% versus 0.8%) and a cardiac arrhythmia (3.9% versus 1.6%). 
 Atrial fibrillation was detected on analysis of electrocardiograms in 6 vildagliptin treated and 0 
placebo treated patients.  Of the 11 deaths in the vildagliptin group, 7 were attributed to 
cardiovascular causes (5 to cardiorespiratory arrest or sudden death and 2 to myocardial 
ischaemia or infarction), 2 to cancer, 1 to infection and 1 to intestinal obstruction.  All 4 deaths 
in the placebo group were attributed to cardiovascular causes. 
 
Other adverse events 
Reports of hypoglycemia were similar in the two treatment groups (4.7% with vildagliptin 
versus 5.6% with placebo).  Two hepatic adverse events were confirmed on adjudication, both 
in the vildagliptin group.  One was a case of cirrhosis and the other jaundice secondary to 
hepatocellular carcinoma, but neither was considered as drug related.  No predefined 
significant elevations in transaminases or bilirubin occurred in either treatment group.  One 
patient in the vildagliptin group died from hepatic cancer. No cases of pancreatitis were 
reported. There were no cases of angioedema confirmed by the adjudication committee. 
 
Other findings 
There were no significant differences between treatment groups for change from baseline to 
end of study in weight, heart rate, blood pressure, estimated glomerular filtration rate or urinary 
albumin to creatinine ratio.   
 
 
  
 DISCUSSION 
The primary goal of this safety study was to evaluate the effect of vildagliptin 50 mg twice 
daily, compared with placebo, added to conventional treatment for diabetes, on LVEF in 
patients with HF-REF.  The study met the pre-specified objective of showing non-inferiority 
i.e. showed that vildagliptin, compared with placebo, did not cause a major reduction in LVEF.  
Indeed, mean LVEF increased slightly from baseline in each treatment group.  Two other 
findings, however, were unexpected and merit comment. Firstly, we showed that left 
ventricular volumes increased with vildagliptin treatment and secondly there were more deaths 
in the vildagliptin group compared with the placebo group.   
The increase in left ventricular volumes is hard to explain and could reflect baseline 
imbalances (see Results) or the play of chance.  Baseline end-diastolic volume was higher in 
the vildagliptin group, as was BNP concentration and the percentage of patients with prior 
hospitalization for HF, suggesting that the patients in this group might have also been more 
susceptible to adverse left ventricular remodeling.  However, if vildagliptin induced adverse 
left ventricular remodeling, a decline in LVEF and a rise in BNP would have been expected. 
Instead we observed a slightly greater increase in LVEF and trend to a greater reduction in 
BNP  in the vildagliptin group, although neither trend was significant. Similarly, adverse 
remodeling might also have been reflected in evidence of worsening heart failure which was 
not seen.   
On the other hand, the potentially harmful consequences of left ventricular enlargement, if real, 
cannot be ignored.  Increase in left ventricular volume is associated with worse clinical 
outcomes, including mortality, in heart failure
21,22
This draws attention to the second surprising 
observation in the present study which was of a higher mortality rate in the vildagliptin group.  
However, the total number of deaths was small and the imbalance in deaths attributable to a 
cardiovascular cause deaths was 7 versus 4 (with none in the vildagliptin group attributed to 
 worsening heart failure).  We believe, therefore, this imbalance most likely reflects the play of 
chance.  
 However, it is not certain that all DPP-4 inhibitors are safe in patients with heart failure. In the 
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus 
Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial, the DPP-4 inhibitor studied 
led to a significant increase in risk of hospitalization for heart failure (289 versus 228 patients; 
P=0.007).
12,16
 Treatment with a different DPP-4 inhibitor in the Examination of Cardiovascular 
Outcomes With Alogliptin vs Standard of Care (EXAMINE) trial also led to a higher rate of 
hospitalization for heart failure although the difference from placebo was not statistically 
significant (106 versus 89 patients; P=0.22).
 13,17 
Conversely, there was no suggestion of an 
increased risk of heart failure hospitalization (228 versus 229 patients; P=0.95) in the Trial 
Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).
 14,15 
It should be noted that the 
above mentioned trials were not conducted specifically in patients with heart failure and the 
minority of patients with heart failure at baseline in those trials were not phenotyped according 
to left ventricular function (and nor were those hospitalized during follow-up).
 15,17 
VIVIDD 
was quite different in testing the effects of a DPP-4 inhibitor in patients with established heart 
failure and documented reduced left ventricular ejection fraction. While heart failure-related 
hospitalizations did not occur more frequently with vildagliptin (13 vs. 10 events, p=0.55) in 
the present study, our trial was small and was not powered to detect differences in clinical 
outcomes. Consequently, we could have missed a safety signal in VIVIDD.  Indeed, in a trial 
very similar to the present one in terms of design and size assessing the thiazolidinedione  
rosiglitazone in patients with systolic heart failure, the difference between rosiglitazone and 
placebo in change in LVEF from baseline was 1.49 (-0.32, 3.30;  p=0.10), fulfilling non-
inferiority according to the same criterion used in the present trial.
11
  Rosiglitazone did not 
increase left ventricular volumes (although did raise BNP).
11
 Despite this, it is clear that 
glitazones increase the risk of developing heart failure and the risk of worsening in patients 
 with heart failure.
8,9
 Consequently, while all of the concerning findings in the various DPP-4 
inhibitor trials described above may be due to chance and unrelated, the possibility exists that 
these drugs could have adverse effects on myocardial structure and function. In relation to this, 
it is also worth examining the GLP-1 receptor agonist trials which used agents sharing a similar 
(but not identical) mechanism of action to that of the DPP-4 inhibitors. In three large trials 
including patients largely free of heart failure at baseline, lixisenatide, liraglutide and 
semaglutide had a neutral effect on heart failure outcomes.
23-25
 However, in two small studies 
in patients with established HF-REF there was the suggestion (but not definitive evidence) that 
treatment with liraglutide might lead to worse outcomes compared with placebo.
26,27 
In animal 
studies of myocardial infarction, DDP-4 inhibitors (including vildagliptin) have shown either a 
neutral or favorable effect on left ventricular remodeling.
28-30
 
 
Inevitably, the present study has limitations.  While sufficiently powered to evaluate the 
primary endpoint, it was still a relatively small trial and was not powered to robustly assess 
clinical outcomes.  There was a small difference in baseline left ventricular volumes that could 
have influenced subsequent changes in these measurements.  The rate of discontinuation was 
relatively high (Figure 2) and only 70% of patients completing the study as per protocol 
without major protocol deviations had at least one follow-up echocardiogram 22 or more weeks 
after randomization, although the number of patients with at least 2 analysable 
echocardiograms was more than needed according to our power calculations.  
 
In conclusion, although the present study showed that vildagliptin was non-inferior to placebo 
with respect to change in LVEF, it did show that use of this DPP-4 inhibitor was associated 
with an increase in left ventricular volumes. However, there was no increase in BNP or any 
other indication of worsening heart failure status.  Whether the increase in ventricular volumes 
indicates some unexplained action of vildagliptin on left ventricular remodeling or a chance 
 finding is unknown, as are its clinical implications. More evidence is needed regarding the 
safety of DPP-4 inhibitors in patients with established heart failure and left ventricular systolic 
dysfunction. 
 
Clinical Perspectives 
Competency in medical knowledge:  
While it is now accepted that the cardiovascular safety of new glucose-lowering treatments for 
type 2 diabetes must be demonstrated before marketing, there is no specific requirement to 
show safety in patients with heart failure and reduced ejection fraction (HFrEF). This is despite 
evidence that at least one class of hypoglycemic drugs, the thiazolidinediones, can lead to the 
worsening of heart failure. We studied the safety of the dipeptidyl peptidase-4 inhibitor, 
vildagliptin, in patients with type 2 diabetes and HFrEF by measuring change in left ventricular 
ejection fraction (LVEF) over 52 weeks.  Although vildagliptin, compared with placebo, met 
the prespecified non-inferiority margin for safety, vildagliptin led to an unexpected an 
unexplained increase in left ventricular volumes. 
 
Translational outlook: 
While the clinical significance of our findings is unknown, there are other data with an agent in 
the same class, saxagliptin, showing an increase in risk of incident heart failure hospitalization. 
While both sets of results may reflect the play of chance, they do, along with the earlier 
thiazolidinedione findings, highlight the need to examine the safety of new glucose-lowering 
treatments specifically in patients with diabetes and HFrEF who are a particularly high risk and 
possibly vulnerable group. 
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Table 1: Baseline characteristics of patients and treatment 
 Vildagliptin 
n=128 
Placebo 
n=126 
Age, years (SD) 62.9 (8.5) 63.4 (9.3) 
Female sex, n (%) 29 (22.7) 30 (23.8) 
BMI, kg/m
2
 (SD) 29.6 (4.6) 29.3 (4.7) 
Obese, (%) 54 (42.2) 50 (39.7) 
Current smoker, n (%) 21(16.4) 9 (7.1) 
Systolic BP, mmHg (SD) 130.4 (16.3) 127.9 (15.3) 
Diastolic BP, mmHg (SD) 77.6 (8.9) 77.2 (8.7) 
Heart rate, bpm (SD) 73.1 (10.1) 73.5 (9.3) 
History, n (%) 
Myocardial infarction 
Angina pectoris 
CABG 
PCI 
Stroke 
Atrial fibrillation 
Hypertension 
Prior hospitalization for   HF 
COPD 
 
80 (62.5) 
55 (43.0) 
30 (23.4) 
24 (18.8) 
12 (9.4) 
29 (22.7) 
112 (87.5) 
66 (51.6) 
16 (12.5) 
 
79 (62.7) 
49 (38.9) 
30 (23.8) 
22 (17.5) 
11 (8.7) 
34 (27.0) 
108 (85.7) 
55 (43.7) 
8 (6.3) 
Diabetes status 
Duration of diabetes, years (SD) 
Hemoglobin A1c, % (SD) 
 
9.5 (8.1) 
7.8 (0.95) 
 
9.1 (7.8) 
7.8 (1.07) 
  
 Vildagliptin 
n=128 
Placebo 
n=126 
Heart failure status 
NYHA class, n (%) 
I 
II 
III 
LVEF, % (SD) 
LVEF ≤ 35 %, n (%) 
BNP pg/ml (IQR)* 
 
 
13 (10.2) 
68 (53.1) 
47 (36.7) 
30.6 (6.8) 
91 (71.1) 
244 (133, 558) 
 
 
12 (9.5) 
66 (52.4) 
48 (38.1) 
29.6 (7.7) 
96 (74.2) 
217 (113, 430) 
Treatment, % 
ACE inhibitor  
ARB 
Beta-blocker 
MRA 
Digitalis glycoside 
Diuretic  (loop) 
ICD 
CRT 
Insulin 
Monotherapy 
Any 
 
 
71.8 
23.4 
79.7 
46.1 
28.9 
71.1 
9.4 
10.2 
 
24.2 
35.2 
 
 
61.9 
28.6 
76.2 
37.3 
23.0 
70.7 
7.9 
11.9 
 
24.6 
33.3 
 
 
  
  Vildagliptin 
n=128 
Placebo 
n=126 
Treatment, % (continued) 
Oral anti-diabetes therapy 
Sulfonylurea 
Metformin 
AGI 
Glinide 
Any oral therapy 
Diet only 
 
 
46.9 
36.7 
0.8 
1.6 
63.3 
12.5 
 
 
53.2 
32.5 
2.4 
0 
68.3 
7.1 
 
All values are mean unless indicated. 
 
BMI = body mass index; BNP = B-type natriuretic peptide; BP = blood pressure; ACE = 
angiotensin converting enzyme; bpm = beats per minute; ARB = angiotensin receptor blocker; 
CABG = coronary artery bypass grafting; MRA = mineralocorticoid receptor antagonist; PCI = 
percutaneous coronary intervention; ICD = implantable cardioverter defibrillator; NYHA = 
New York Heart Association; CRT = cardiac resynchronisation therapy; LVEF = left 
ventricular ejection fraction; AGI = alpha-glucosidase inhibitor; * = median 
 
  
  
Table 2: Baseline echocardiographic measurements 
 Vildagliptin 
(n=128*) 
Placebo 
(n=126*) 
LVIDD, cm (SD)
+
 5.9 (0.91) 5.9 (0.93) 
LVISD, cm (SD)
 +
 5.2 (0.93) 5.2 (0.91) 
LVEDV*, ml (SD) 179 (59) 168 (66) 
LVESV*, ml (SD) 125 (44) 120 (56) 
LVSV, ml (SD) 54.3 (21.0) 48.1 (18.3) 
LVEF, % (SD) 30.6 (6.8) 29.6 (7.7) 
LV-SWT, cm (SD) 1.0 (0.24) 1.0 (0.25) 
LV-PWT, cm (SD) 1.0 (0.20) 1.0 (0.21) 
LVMi, g/m
2 
(SD) 134 (39) 130 (41) 
 
* not all  measurements were obtained in every patient  
+
LVEDVi 92 ml/m
2
   LVESVi 65 ml/m
2
 
 
LVIDD = left ventricular internal diastolic dimension; LVISD = left ventricular internal 
systolic dimension; LVEDV = left ventricular end diastolic volume; LVESV= left ventricular 
end systolic volume; LVEF = left ventricular ejection fraction; LVSV = left ventricular stroke 
volume; LV-SWT = left ventricular septal wall thickness; LV-PWT = left ventricular posterior 
wall thickness; LVMi = left ventricular mass index; LVEDVi = left ventricular end diastolic 
volume index; LVESVi = left ventricular end systolic volume index 
 Table 3: Non-fatal cardiovascular events and deaths. 
 
 Vildagliptin 
(n=128) 
Placebo 
(n=126) 
Rate 
Difference, % 
(95% CI) 
Any fatal or non-fatal cardiovascular event, n 
(%)* 
35 (27.3) 31 (24.6) 2.7  
(-9.5,  15.0) 
Death from cardiovascular causes 7 (5.5) 4 (3.2) 2.3  
(-10.3,  14.6) 
Worsening heart failure 23 (18.0) 22 (17.5) 0.5  
(-11.9,  12.7) 
Acute coronary syndrome 7 (5.5) 3 (2.4) 3.1  
(-9.5, 15.4) 
Cardiac arrhythmia 9 (7.0) 4 (3.2) 3.9  
(-8.7, 16.1) 
Stroke 1 (0.8) 4 (3.2) -2.4  
(-14.9, 10.1) 
Death from any cause, n (%) 11 (8.6) 4 (3.2) 5.4  
(-7.2, 17.6) 
* Patients counted only once, even if multiple events. There were 4 non-cardiovascular deaths 
in the vildagliptin group: from hepatic neoplasm, lung neoplasm, septic shock, and surgery for 
intestinal obstruction due to peritoneal adhesions. 
  
 
  
  
 
Figure 1: Study timeline  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2: Flow chart of participants 
 
 
 
 
  
 Figure 3. Change from baseline in left ventricular ejection fraction (primary endpoint) 
and other echocardiographic measures 
 
 
 
A. Change in LVEF (%). Difference in adjusted mean change 0.62 (95% CI: -2.21, 3.44; 
P=0.667)*. 
*Meets criteria for non-inferiority to comparator as the lower limit of the two sided 95% CI for 
the difference in mean change in LVEF is greater than -3.5%. Primary analysis is based on Per 
Protocol. B. Change in LVEDV (mL). Difference in adjusted mean change 17.06 (95% CI: 
4.62, 29.51; P=0.007). Full analysis set. C. Change in LVESV. Difference in adjusted mean 
change 9.44 (95% CI: -0.49, 19.38; P=0.062). Full analysis set.  D. Change in LVSV. 
Difference in adjusted mean change 9.00 (95% CI: 3.38, 14.62; P=0.002). Full analysis set. 
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ABSTRACT 
Objectives: To study the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients 
with heart failure and reduced ejection fraction. 
 
Background: Many patients with type 2 diabetes mellitus have heart failure and it is important 
to know about the safety of new treatments for diabetes in these individuals. 
 
Methods: Patients aged 18 to 85 years with type 2 diabetes and heart failure (New York Heart 
Association functional class I to III and left ventricular ejection fraction [LVEF] < 0.40) were 
randomized to 52 weeks treatment with vildagliptin 50 mg twice daily (50 mg once daily if 
treated with a sulfonylurea) or matching placebo.  The primary endpoint was between-
treatment change from baseline in echocardiographic LVEF using a non-inferiority margin of -
3.5%.   
 
Findings:  254 patients were randomly assigned to vildagliptin (n=128) or placebo (n=126).  
Baseline LVEF was 30.6 (SD 6.8)% in the vildagliptin group and 29.6 (7.7)% in the placebo 
group.  The adjusted mean change in LVEF was 4.95 (SE 1.25)% in vildagliptin treated 
patients and 4.33 (1.23)% in placebo treated patients – a difference of 0.62 (95% CI -2.21, 
3.44); p=0.667.  This difference met the predefined non-inferiority margin of -3.5%. Left 
ventricular end-diastolic and end-systolic volumes increased more in the vildagliptin group: by 
17.1 (4.6, 29.5) ml; p=0.007 and 9.4 (-0.49, 19.4) ml; p=0.062, respectively.  Decrease in 
haemoglobin A1c from baseline to 16 weeks, the main secondary endpoint, was greater in the 
vildagliptin group: -0.62 (-0.93, -0.30); p<0.001. 
 
4 
 
Conclusions:  Compared with placebo, vildagliptin had no major effect on LVEF but did lead 
to an increase in left ventricular volumes, the cause and clinical significance of which is 
unknown. More evidence is needed regarding the safety of dipeptidyl peptidase-4 inhibitors in 
patients with heart failure and left ventricular systolic dysfunction. 
 
Key words: Diabetes, Heart Failure. 
 
Trial registration: ClinicalTrials.gov NCT00894868 
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INTRODUCTION 
Type 2 diabetes is common in patients with heart failure with reported prevalences of between 
25 and 40 per cent in trials and registries.
1-5
  Heart failure patients with diabetes have worse 
symptoms, greater functional limitation and higher rates of hospitalization and death than 
heart failure patients without diabetes.
1-5
  The safety of established treatments for diabetes in 
patients with heart failure is uncertain.  While there are no known concerns about 
sulfonylureas and insulin, it has been thought that metformin might increase the risk of lactic 
acidosis although this has never been demonstrated.
6,7
 Thiazolidinediones increase the risk of 
patients with diabetes developing heart failure.
8,9
  Thiazolidinediones also increase the risk of 
worsening of heart failure in patients with that condition.
10,11
 
 
Consequently, it is important that the safety of new treatments for diabetes is studied in 
patients with heart failure.  One group of new treatments are the dipeptidyl peptidase-4 (DPP-
4) inhibitors which block the degradation of endogenous glucagon-like peptide-1 (GLP-1) and 
glucose dependent insulinotropic polypeptide (GIP) which stimulate insulin secretion in a 
glucose-dependent manner, suppress glucagon release and slow gastric emptying.
12-14
 Three 
recent large randomized controlled trials have reported conflicting evidence about the risk of 
heart failure with different agents in this class.
 15-17 
None, however, characterized patients with 
heart failure at baseline or those developing heart failure during follow-up. Further, none 
examined the effect of a DPP-4 inhibitor on left ventricular ventricular function. Here we 
report a study of the effects of the DPP-4 inhibitor vildagliptin in patients with heart failure 
and reduced ejection fraction (HF-REF).
18,19
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METHODS 
The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD) was a prospective, 
randomized, double-blind, parallel-group trial comparing vildagliptin and placebo, added to 
standard therapy, for 52 weeks in patients with type 2 diabetes and heart failure with a reduced 
ejection fraction.  An ethics committee approved the trial at each site and patients provided 
written informed consent.  Patient safety was reviewed by an independent committee 
throughout the trial and cardiovascular, hepatic and cutaneous (including suspected 
angioedema) adverse events were adjudicated by independent and masked committees.  All 
echocardiographic analyses were carried out by blinded assessors in a core laboratory 
(Perceptive Informatics Inc., a subsidiary of Parexel International - see below).  The study 
results were analysed by Novartis and confirmed by an independent statistician at the 
University of Glasgow (J.L.).  
 
Participants 
In brief, men and women aged between 18 and 85 years with type 2 diabetes (hemoglobin A1c 
6.5% - 10.0%), body mass index 22 – 42 kg/m2, heart failure with a reduced ejection fraction 
(< 40%) and inNew York Heart Association (NYHA) functional class I to III were eligible.  
The key exclusion criteria were NYHA functional class IV, a fasting plasma glucose of ≥15 
mmol/1, thiazolidinedione or incretin therapy, a recent cardiovascular event or procedure, 
creatinine clearance <30 ml/min and liver disease or elevated transaminases or bilirubin. 
 
Randomization and masking 
Eligible patients were randomly assigned in a 1:1 ratio according to a central randomization 
scheme, stratified by NYHA class, to one of two treatment groups: vildagliptin 50 mg twice 
daily (50 mg once daily if concomitant treatment with a sulfonylurea) or placebo.  
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Randomization was conducted using an interactive voice response system.  Vildagliptin and 
placebo were identical in packaging, labelling, appearance and schedule of administration.  
 
Procedures 
From 04 May 2009 (Figure 1), subjects who met the inclusion/exclusion criteria (including 
echocardiographic criteria) at the screening visit entered a 2 to 4 week run-in period during 
which the individuals continued their usual diet, exercise regimen and drug therapy for 
diabetes (if taking drug therapy).  Patients completing this period returned for baseline 
assessment including measurement of B type natriuretic peptide (BNP) and were then 
randomized to vildagliptin or placebo as described above.  Patients were reviewed every 4 
weeks up to week 24 and every 8 weeks thereafter (diabetes “rescue” therapy could be used 
from week 16 onwards). Repeat BNP measurements and echocardiography were performed at 
24 and 52 weeks.  Patients permanently stopping treatment before 52 weeks were asked to 
return for a final assessment, including an echocardiogram and BNP measurement.  NYHA 
class, dyspnea and edema were evaluated at baseline and at each of the follow-up visits, as 
was blood chemistry (including hemoglobin A1c) and hematological measurements.   
 
Echocardiography 
Each echocardiogram was analyzed by a minimum of 2 qualified echocardiographers blinded 
to treatment assignment and according to a pre-specified protocol.  The Simpson biplane 
method of discs was used to calculate LVEF.
20 
 
B-type natriuretic peptide (BNP) 
BNP was measured using a triage Beckman Coulter Immunoassay (Covance Central 
Laboratory services). 
8 
 
Study objectives 
This was a safety study.  The primary objective was to show that vildagliptin was at least non-
inferior to placebo with respect to change in LVEF from baseline to end of study.  
Recognizing that not all patients would complete the planned maximum of 52 weeks of 
treatment and that an effect of drugs on left ventricular remodelling may be apparent within 6 
months, the original protocol was altered during the trial (but before any results were known) 
to define the primary analysis of LVEF to include any patient who had at least one follow-up 
echocardiogram recorded 22 weeks or more after randomization.  The key secondary endpoint 
was change in hemoglobin A1c from baseline to 16 weeks (with censoring for use of rescue 
therapy before that time-point). 
 
Safety assessments 
In addition to conventional adverse event reporting, specific safety assessments were made 
including assessment of NYHA class and breathlessness and edema at each study visit and 
adjudication of suspected worsening heart failure symptoms (see Appendix Table 1), and 
possible cardiovascular, liver and cutaneous events, as well as deaths, by the adjudication 
committees described above. 
 
Statistical analysis 
The study sample size was calculated based upon 90% power and a one-sided significance 
level of 0.025 to declare non-inferiority of vildagliptin, compared with placebo, for the effect 
of treatment of LVEF, using a margin of -3.5% and an expected difference between the two 
treatments of 0%.  The choice of the non-inferiority margin was based on clinical importance 
and prior use.
10
  The calculation was performed using nQuery Advisor version 5.0 and based 
on a LVEF standard deviation (SD) of 7% (derived from prior trials).  We calculated that a 
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total of 172 patients with at least one LVEF measurement after randomization were required.  
The sample-size was inflated to 246 patients to allow for approximately 30% of patients not 
having a LVEF measurement after randomization.  An analysis of co-variance model 
(ANCOVA) was fitted including terms for treatment, baseline LVEF, NYHA class and region.  
The least-square mean (LSM, “adjusted mean”) change from baseline in LVEF was calculated 
for each treatment group and the difference in LSM between the two treatment groups, and the 
two-sided 95% confidence interval (CI), were obtained from this model.  
 
An ANCOVA model fitted with terms for treatment, baseline haemoglobin A1c and region 
was used to analyse LSM change in hemoglobin A1c.  Other exploratory variables were 
analysed in a similar way with appropriate transformations if the normality assumption was 
questionable. The statistical software used was SAS® (Version 9.2). 
  
 RESULTS 
Baseline characteristics and treatment 
A total of 254 patients were randomized at 67 sites in 15 countries.  Their mean age was 63 
years and 77% were male.  Other key demographic characteristics, medical history and 
treatment at baseline are shown in Table 1.  The first patient visit was 04 May 2009 and the last 
patient visit was 13 August 2012. Overall, patients had a mean duration of diabetes of 9.3 years 
(median 6.8 years) and the mean hemoglobin A1c at baseline was 7.8% per cent; 34% of 
patients were treated with metformin and the same proportion with insulin, either as 
monotherapy or in combination with other glucose lowering agents.  The median duration of 
heart failure was 3.3 years, mean left ventricular ejection fraction was 30%, median BNP was 
231 pg/ml and most patients were in NYHA functional class II (53%) or III (37%); 48% of 
patients had a history of hospital admission for heart failure.  More than 90% of patients were 
treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, 78% 
with a beta-blocker and 42% with a mineralocorticoid receptor antagonist. Baseline 
characteristics between treatment groups were well balanced with exception of more patients in 
the vildagliptin treatment group having a history of smoking, prior hospitalization for heart 
failure, or chronic obstructive pulmonary disease. 
 
Follow-up and adherence 
Overall, 101 patients (79%) assigned to vildagliptin and 100 patients (79%) assigned to 
placebo completed the 52 week follow-up as planned (Figure 2).  There were 11 deaths (8.6%) 
in the vildagliptin group and 4 deaths (3.2%) in the placebo group.  Other reasons for not 
completing follow-up were adverse events (5 vildagliptin versus 4 placebo), withdrawal of 
consent (3 versus 10), protocol violation (3 versus 2), loss-to-follow-up (2 versus 2), 
unsatisfactory therapeutic effect (2 versus 1) and administrative problems (1 versus 3).  
 Overall, 16 patients (12.5%) assigned to vildagliptin and 22 patients (17.4%) assigned to 
placebo discontinued study drug early for reasons other than death. 
Primary endpoint: change in LVEF 
LVEF was matched between treatment groups at baseline (Table 2).  The intention to treat 
analysis is shown in Figure 2.  The pre-specified primary analysis (patients with a baseline and 
follow-up measurement of LVEF ≥22 weeks) included 89 patients assigned to vildagliptin 
(mean baseline LVEF 30.5 ± SE 0.67%) and 90 assigned to placebo (29.8 ± SE 0.78%).  The 
adjusted mean change in LVEF was 4.95 (± SE 1.25)% in the vildagliptin group and 4.33 (± 
SE 1.23)% in the placebo group;  a difference of 0.62  (95% confidence interval -2.21, 3.44; 
p=0.667).  This difference met the predefined non-inferiority criterion of -3.5% at p=0.025.  
Analysis of the patients (88 vildagliptin, 89 placebo) with a 48 week follow-up measurement of 
LVEF gave almost identical findings (see sensitivity analyses Appendix Table A2). 
 
Other echocardiographic findings 
Changes in left ventricular volumes are shown in Table 2 and Figure 3.  Left ventricular end-
diastolic volume increased significantly with vildagliptin compared with placebo and there was 
a trend in the same direction for end-systolic volume which was of borderline statistical 
significance (6 and 12 month volumes are shown in Appendix Table A3).  There was a 
significant increase in stroke volume but no change in left ventricular wall thickness or mass. 
 
Secondary endpoint: change in hemoglobin A1c 
The adjusted mean change from baseline to rescue-censored week 16 haemoglobin A1c was -
0.45 (± SE0.12)% in the vildagliptin group and 0.17 (±SE 0.12)% in the placebo group, with an 
adjusted mean difference (vildagliptin – placebo) of -0.62 (95% CI -0.03, -0.30)%; p<0.001.  
The difference at week 52 was -0.36 (95% CI -0.71, -0.02)%; p=0.040. 
  
 Change in B-type natriuretic peptide 
Baseline geometric mean BNP values for those with an end of study measurement were 227 
pg/ml in patients assigned to vildagliptin and 214 pg/ml in those assigned to placebo.  A 
reduction in geometric mean BNP values from baseline was observed in both treatment groups: 
ratio of 52 weeks/baseline: 0.72 (95% CI 0.56, 0.93) in the vildagliptin group (n=75) and 0.86 
(0.67, 1.12) in the placebo group (n=81).  The ratio of ratios (vildagliptin/placebo) was 0.84 
(0.62, 1.14), p=0.252. 
 
Other measures of heart failure status 
Changes in dyspnea and edema from baseline over the course of the study were small and did 
not differ between treatment groups.  There was no difference in change in NYHA class 
distribution between the two treatment groups and the proportion of patients with an increase in 
heart failure medication during the study was 26.6% in the vildagliptin group and 24% in the 
placebo group (p=0.640). Specifically, the proportion of patients taking loop diuretics at 
baseline was 64.8% and 65.9% of patients in the vildagliptin and the placebo groups, 
respectively, and increased during the study to 71.1% and 72.2%, respectively. Worsening 
heart failure (including hospitalisation for heart failure) was confirmed by the endpoint 
committee in 23 patients (18.0%) in the vildagliptin group and 22 patients (17.6%) in the 
placebo group; the number of episodes of worsening was 39 versus 33, respectively [Appendix 
Table A4].  Hospital admissions for heart failure were reported in 13 patients (10.2%) in the 
vildagliptin group and 10 patients (8.0%) in the placebo group (p=0.552). 
 
Other adjudicated cardiovascular events, hepatic events and deaths 
Overall, 19 vildagliptin treated patients (14.8%) and 14 placebo patients (11.2%) were admitted 
to hospital for a cardiovascular cause.  In addition to heart failure (see above), these included 
acute coronary syndrome (6.3% versus 0.8%) and a cardiac arrhythmia (3.9% versus 1.6%). 
 Atrial fibrillation was detected on analysis of electrocardiograms in 6 vildagliptin treated and 0 
placebo treated patients.  Of the 11 deaths in the vildagliptin group, 7 were attributed to 
cardiovascular causes (5 to cardiorespiratory arrest or sudden death and 2 to myocardial 
ischaemia or infarction), 2 to cancer, 1 to infection and 1 to intestinal obstruction.  All 4 deaths 
in the placebo group were attributed to cardiovascular causes. 
 
Other adverse events 
Reports of hypoglycemia were similar in the two treatment groups (4.7% with vildagliptin 
versus 5.6% with placebo).  Two hepatic adverse events were confirmed on adjudication, both 
in the vildagliptin group.  One was a case of cirrhosis and the other jaundice secondary to 
hepatocellular carcinoma, but neither was considered as drug related.  No predefined 
significant elevations in transaminases or bilirubin occurred in either treatment group.  One 
patient in the vildagliptin group died from hepatic cancer. No cases of pancreatitis were 
reported. There were no cases of angioedema confirmed by the adjudication committee. 
 
Other findings 
There were no significant differences between treatment groups for change from baseline to 
end of study in weight, heart rate, blood pressure, estimated glomerular filtration rate or urinary 
albumin to creatinine ratio.   
 
 
  
 DISCUSSION 
The primary goal of this safety study was to evaluate the effect of vildagliptin 50 mg twice 
daily, compared with placebo, added to conventional treatment for diabetes, on LVEF in 
patients with HF-REF.  The study met the pre-specified objective of showing non-inferiority 
i.e. showed that vildagliptin, compared with placebo, did not cause a major reduction in LVEF.  
Indeed, mean LVEF increased slightly from baseline in each treatment group.  Two other 
findings, however, were unexpected and merit comment. Firstly, we showed that left 
ventricular volumes increased with vildagliptin treatment and secondly there were more deaths 
in the vildagliptin group compared with the placebo group.   
The increase in left ventricular volumes is hard to explain and could reflect baseline 
imbalances (see Results) or the play of chance.  Baseline end-diastolic volume was higher in 
the vildagliptin group, as was BNP concentration and the percentage of patients with prior 
hospitalization for HF, suggesting that the patients in this group might have also been more 
susceptible to adverse left ventricular remodeling.  However, if vildagliptin induced adverse 
left ventricular remodeling, a decline in LVEF and a rise in BNP would have been expected. 
Instead we observed a slightly greater increase in LVEF and trend to a greater reduction in 
BNP  in the vildagliptin group, although neither trend was significant. Similarly, adverse 
remodeling might also have been reflected in evidence of worsening heart failure which was 
not seen.   
On the other hand, the potentially harmful consequences of left ventricular enlargement, if real, 
cannot be ignored.  Increase in left ventricular volume is associated with worse clinical 
outcomes, including mortality, in heart failure
21,22
This draws attention to the second surprising 
observation in the present study which was of a higher mortality rate in the vildagliptin group.  
However, the total number of deaths was small and the imbalance in deaths attributable to a 
cardiovascular cause deaths was 7 versus 4 (with none in the vildagliptin group attributed to 
 worsening heart failure).  We believe, therefore, this imbalance most likely reflects the play of 
chance.  
 However, it is not certain that all DPP-4 inhibitors are safe in patients with heart failure. In the 
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus 
Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial, the DPP-4 inhibitor studied 
led to a significant increase in risk of hospitalization for heart failure (289 versus 228 patients; 
P=0.007).
12,16
 Treatment with a different DPP-4 inhibitor in the Examination of Cardiovascular 
Outcomes With Alogliptin vs Standard of Care (EXAMINE) trial also led to a higher rate of 
hospitalization for heart failure although the difference from placebo was not statistically 
significant (106 versus 89 patients; P=0.22).
 13,17 
Conversely, there was no suggestion of an 
increased risk of heart failure hospitalization (228 versus 229 patients; P=0.95) in the Trial 
Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).
 14,15 
It should be noted that the 
above mentioned trials were not conducted specifically in patients with heart failure and the 
minority of patients with heart failure at baseline in those trials were not phenotyped according 
to left ventricular function (and nor were those hospitalized during follow-up).
 15,17 
VIVIDD 
was quite different in testing the effects of a DPP-4 inhibitor in patients with established heart 
failure and documented reduced left ventricular ejection fraction. While heart failure-related 
hospitalizations did not occur more frequently with vildagliptin (13 vs. 10 events, p=0.55) in 
the present study, our trial was small and was not powered to detect differences in clinical 
outcomes. Consequently, we could have missed a safety signal in VIVIDD.  Indeed, in a trial 
very similar to the present one in terms of design and size assessing the thiazolidinedione  
rosiglitazone in patients with systolic heart failure, the difference between rosiglitazone and 
placebo in change in LVEF from baseline was 1.49 (-0.32, 3.30;  p=0.10), fulfilling non-
inferiority according to the same criterion used in the present trial.
11
  Rosiglitazone did not 
increase left ventricular volumes (although did raise BNP).
11
 Despite this, it is clear that 
glitazones increase the risk of developing heart failure and the risk of worsening in patients 
 with heart failure.
8,9
 Consequently, while all of the concerning findings in the various DPP-4 
inhibitor trials described above may be due to chance and unrelated, the possibility exists that 
these drugs could have adverse effects on myocardial structure and function. In relation to this, 
it is also worth examining the GLP-1 receptor agonist trials which used agents sharing a similar 
(but not identical) mechanism of action to that of the DPP-4 inhibitors. In three large trials 
including patients largely free of heart failure at baseline, lixisenatide, liraglutide and 
semaglutide had a neutral effect on heart failure outcomes.
23-25
 However, in two small studies 
in patients with established HF-REF there was the suggestion (but not definitive evidence) that 
treatment with liraglutide might lead to worse outcomes compared with placebo.
26,27 
In animal 
studies of myocardial infarction, DDP-4 inhibitors (including vildagliptin) have shown either a 
neutral or favorable effect on left ventricular remodeling.
28-30
 
 
Inevitably, the present study has limitations.  While sufficiently powered to evaluate the 
primary endpoint, it was still a relatively small trial and was not powered to robustly assess 
clinical outcomes.  There was a small difference in baseline left ventricular volumes that could 
have influenced subsequent changes in these measurements.  The rate of discontinuation was 
relatively high (Figure 2) and only 70% of patients completing the study as per protocol 
without major protocol deviations had at least one follow-up echocardiogram 22 or more weeks 
after randomization, although the number of patients with at least 2 analysable 
echocardiograms was more than needed according to our power calculations.  
 
In conclusion, although the present study showed that vildagliptin was non-inferior to placebo 
with respect to change in LVEF, it did show that use of this DPP-4 inhibitor was associated 
with an increase in left ventricular volumes. However, there was no increase in BNP or any 
other indication of worsening heart failure status.  Whether the increase in ventricular volumes 
indicates some unexplained action of vildagliptin on left ventricular remodeling or a chance 
 finding is unknown, as are its clinical implications. More evidence is needed regarding the 
safety of DPP-4 inhibitors in patients with established heart failure and left ventricular systolic 
dysfunction. 
 
Clinical Perspectives 
Competency in medical knowledge:  
While it is now accepted that the cardiovascular safety of new glucose-lowering treatments for 
type 2 diabetes must be demonstrated before marketing, there is no specific requirement to 
show safety in patients with heart failure and reduced ejection fraction (HFrEF). This is despite 
evidence that at least one class of hypoglycemic drugs, the thiazolidinediones, can lead to the 
worsening of heart failure. We studied the safety of the dipeptidyl peptidase-4 inhibitor, 
vildagliptin, in patients with type 2 diabetes and HFrEF by measuring change in left ventricular 
ejection fraction (LVEF) over 52 weeks.  Although vildagliptin, compared with placebo, met 
the prespecified non-inferiority margin for safety, vildagliptin led to an unexpected an 
unexplained increase in left ventricular volumes. 
 
Translational outlook: 
While the clinical significance of our findings is unknown, there are other data with an agent in 
the same class, saxagliptin, showing an increase in risk of incident heart failure hospitalization. 
While both sets of results may reflect the play of chance, they do, along with the earlier 
thiazolidinedione findings, highlight the need to examine the safety of new glucose-lowering 
treatments specifically in patients with diabetes and HFrEF who are a particularly high risk and 
possibly vulnerable group. 
 
  
 REFERENCES 
1. MacDonald MR, Petrie MC, Hawkins et al. Diabetes, left ventricular systolic 
dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-40.  
 
2. MacDonald MR, Petrie MC, Varyani F, et al; CHARM Investigators.. Impact of 
diabetes on outcomes in patients with low and preserved ejection fraction heart failure: 
an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality 
and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-85.  
 
3. Dauriz M, Targher G, Laroche C, et al; ESC-HFA Heart Failure Long-Term Registry.. 
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a 
Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From 
the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017; 40: 671-678.  
 
4. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to 
functional capacity in patients with congestive heart failure. Eur Heart J 2000; 21: 
1368-75.  
 
5. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular 
outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014 
Oct;2(10):843-51.  
 
6. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use 
in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic 
Liver Disease: A Systematic Review. Ann Intern Med 2017; 166: 191-200.  
 7. Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-
lowering agents in patients with diabetes. Eur J Heart Fail 2017; 19: 43-53.  
 
8. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with 
rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 
31: 824-31.  
 
9. Hernandez AV, Usmani A, Rajamanickam A, et al. Thiazolidinediones and risk of heart 
failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and 
meta-regression analysis of placebo-controlled randomized clinical trials. Am J 
Cardiovasc Drugs 2011; 11: 115-28. 
 
10. Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglitazone vs glyburide 
in early heart failure: insights from a randomized controlled study of patients with type 
2 diabetes and mild cardiac disease. Congest Heart Fail 2010; 16: 111-7.  
 
11. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial 
assessing the effects of rosiglitazone on echocardiographic function and cardiac status 
in type 2 diabetic patients with New York Heart Association Functional Class I or II 
Heart Failure. J Am Coll Cardiol 2007; 49: 1696-704.  
 
12. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and 
Investigators.. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes 
mellitus. N Engl J Med 2013; 369: 1317-26.  
 
 13. White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators.. Alogliptin after 
acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 
1327-35.  
 
14. Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of Sitagliptin 
on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-42. 
 
15. McGuire DK, Van de Werf F, Armstrong PW, et al; Trial Evaluating Cardiovascular 
Outcomes With Sitagliptin (TECOS) Study Group.. Association Between Sitagliptin 
Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes 
Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2016; 1: 
126-35.  
 
16. Scirica BM, Braunwald E, Raz I, et al; SAVOR-TIMI 53 Steering Committee and 
Investigators.. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the 
SAVOR-TIMI 53 Randomized Trial. Circulation 2015; 132: e198. 
 
17. Zannad F, Cannon CP, Cushman WC, et al; EXAMINE Investigators.. Heart failure and 
mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in 
EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-76.  
 
18. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin 
Pharmacokinet 2012;5 1: 147-62. 
 
 19. Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 
diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 2012; 37: 
386-98.  
 
20. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane 
two-dimensional echocardiography. Circulation 1979; 60: 547-55.. 
 
21. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: 
a credible surrogate endpoint. J Card Fail 2003; 9: 350-3.  
 
22. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: 
a consensus paper from an international forum on cardiac remodeling. Behalf of an 
International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-82.  
 
23. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee.; 
LEADER Trial Investigators.. Liraglutide and Cardiovascular Outcomes in Type 2 
Diabetes. N Engl J Med 2016; 375: 311-22. 
 
24. Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators.. Lixisenatide in Patients 
with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-
57. 
 
25. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators.. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 
1834-1844.  
 
  
26. Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 
analogue, on left ventricular function in stable chronic heart failure patients with and 
without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled 
trial. Eur J Heart Fail 2017; 19: 69-77. 
 
27. Margulies KB, Hernandez AF, Redfield MM, et al; NHLBI Heart Failure Clinical 
Research Network.. Effects of Liraglutide on Clinical Stability Among Patients With 
Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
JAM. 2016; 316: 500-8. 
28. Inthachai T, Lekawanvijit S, Kumfu S, Apaijai N, Pongkan W, Chattipakorn SC, 
Chattipakorn N. Dipeptidyl peptidase-4 inhibitor improves cardiac function by 
attenuating adverse cardiac remodelling in rats with chronic myocardial 
infarction. Exp Physiol. 2015;100:667-79. 
29. Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, Gilbert RE. DPP-4  
inhibition attenuates cardiac dysfunction and adverse remodeling following 
myocardial infarction in rats with experimental diabetes. Cardiovasc Ther. 
2013;31:259-67. 
30. Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects 
of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart 
failure. Cardiovasc Diabetol. 2011;10:85. 
 
 TABLE LEGEND 
Table 1 Baseline characteristics of patients and treatment 
 
Table 2 Baseline echocardiographic measurements 
 
Table 3 Non-fatal cardiovascular events and deaths 
 
FIGURE LEGEND 
Figure 1 Study timeline 
 
Figure 2 Flow chart of participants 
 
Figure 3 Change from baseline in left ventricular ejection fraction (primary endpoint) and 
other echocardiographic measures 
  
  
Table 1: Baseline characteristics of patients and treatment 
 Vildagliptin 
n=128 
Placebo 
n=126 
Age, years (SD) 62.9 (8.5) 63.4 (9.3) 
Female sex, n (%) 29 (22.7) 30 (23.8) 
BMI, kg/m
2
 (SD) 29.6 (4.6) 29.3 (4.7) 
Obese, (%) 54 (42.2) 50 (39.7) 
Current smoker, n (%) 21(16.4) 9 (7.1) 
Systolic BP, mmHg (SD) 130.4 (16.3) 127.9 (15.3) 
Diastolic BP, mmHg (SD) 77.6 (8.9) 77.2 (8.7) 
Heart rate, bpm (SD) 73.1 (10.1) 73.5 (9.3) 
History, n (%) 
Myocardial infarction 
Angina pectoris 
CABG 
PCI 
Stroke 
Atrial fibrillation 
Hypertension 
Prior hospitalization for   HF 
COPD 
 
80 (62.5) 
55 (43.0) 
30 (23.4) 
24 (18.8) 
12 (9.4) 
29 (22.7) 
112 (87.5) 
66 (51.6) 
16 (12.5) 
 
79 (62.7) 
49 (38.9) 
30 (23.8) 
22 (17.5) 
11 (8.7) 
34 (27.0) 
108 (85.7) 
55 (43.7) 
8 (6.3) 
Diabetes status 
Duration of diabetes, years (SD) 
Hemoglobin A1c, % (SD) 
 
9.5 (8.1) 
7.8 (0.95) 
 
9.1 (7.8) 
7.8 (1.07) 
  
 Vildagliptin 
n=128 
Placebo 
n=126 
Heart failure status 
NYHA class, n (%) 
I 
II 
III 
LVEF, % (SD) 
LVEF ≤ 35 %, n (%) 
BNP pg/ml (IQR)* 
 
 
13 (10.2) 
68 (53.1) 
47 (36.7) 
30.6 (6.8) 
91 (71.1) 
244 (133, 558) 
 
 
12 (9.5) 
66 (52.4) 
48 (38.1) 
29.6 (7.7) 
96 (74.2) 
217 (113, 430) 
Treatment, % 
ACE inhibitor  
ARB 
Beta-blocker 
MRA 
Digitalis glycoside 
Diuretic  (loop) 
ICD 
CRT 
Insulin 
Monotherapy 
Any 
 
 
71.8 
23.4 
79.7 
46.1 
28.9 
71.1 
9.4 
10.2 
 
24.2 
35.2 
 
 
61.9 
28.6 
76.2 
37.3 
23.0 
70.7 
7.9 
11.9 
 
24.6 
33.3 
 
 
  
  Vildagliptin 
n=128 
Placebo 
n=126 
Treatment, % (continued) 
Oral anti-diabetes therapy 
Sulfonylurea 
Metformin 
AGI 
Glinide 
Any oral therapy 
Diet only 
 
 
46.9 
36.7 
0.8 
1.6 
63.3 
12.5 
 
 
53.2 
32.5 
2.4 
0 
68.3 
7.1 
 
All values are mean unless indicated. 
 
BMI = body mass index; BNP = B-type natriuretic peptide; BP = blood pressure; ACE = 
angiotensin converting enzyme; bpm = beats per minute; ARB = angiotensin receptor blocker; 
CABG = coronary artery bypass grafting; MRA = mineralocorticoid receptor antagonist; PCI = 
percutaneous coronary intervention; ICD = implantable cardioverter defibrillator; NYHA = 
New York Heart Association; CRT = cardiac resynchronisation therapy; LVEF = left 
ventricular ejection fraction; AGI = alpha-glucosidase inhibitor; * = median 
 
  
  
Table 2: Baseline echocardiographic measurements 
 Vildagliptin 
(n=128*) 
Placebo 
(n=126*) 
LVIDD, cm (SD)
+
 5.9 (0.91) 5.9 (0.93) 
LVISD, cm (SD)
 +
 5.2 (0.93) 5.2 (0.91) 
LVEDV*, ml (SD) 179 (59) 168 (66) 
LVESV*, ml (SD) 125 (44) 120 (56) 
LVSV, ml (SD) 54.3 (21.0) 48.1 (18.3) 
LVEF, % (SD) 30.6 (6.8) 29.6 (7.7) 
LV-SWT, cm (SD) 1.0 (0.24) 1.0 (0.25) 
LV-PWT, cm (SD) 1.0 (0.20) 1.0 (0.21) 
LVMi, g/m
2 
(SD) 134 (39) 130 (41) 
 
* not all  measurements were obtained in every patient  
+
LVEDVi 92 ml/m
2
   LVESVi 65 ml/m
2
 
 
LVIDD = left ventricular internal diastolic dimension; LVISD = left ventricular internal 
systolic dimension; LVEDV = left ventricular end diastolic volume; LVESV= left ventricular 
end systolic volume; LVEF = left ventricular ejection fraction; LVSV = left ventricular stroke 
volume; LV-SWT = left ventricular septal wall thickness; LV-PWT = left ventricular posterior 
wall thickness; LVMi = left ventricular mass index; LVEDVi = left ventricular end diastolic 
volume index; LVESVi = left ventricular end systolic volume index 
 Table 3: Non-fatal cardiovascular events and deaths. 
 
 Vildagliptin 
(n=128) 
Placebo 
(n=126) 
Rate 
Difference, % 
(95% CI) 
Any fatal or non-fatal cardiovascular event, n 
(%)* 
35 (27.3) 31 (24.6) 2.7  
(-9.5,  15.0) 
Death from cardiovascular causes 7 (5.5) 4 (3.2) 2.3  
(-10.3,  14.6) 
Worsening heart failure 23 (18.0) 22 (17.5) 0.5  
(-11.9,  12.7) 
Acute coronary syndrome 7 (5.5) 3 (2.4) 3.1  
(-9.5, 15.4) 
Cardiac arrhythmia 9 (7.0) 4 (3.2) 3.9  
(-8.7, 16.1) 
Stroke 1 (0.8) 4 (3.2) -2.4  
(-14.9, 10.1) 
Death from any cause, n (%) 11 (8.6) 4 (3.2) 5.4  
(-7.2, 17.6) 
* Patients counted only once, even if multiple events. There were 4 non-cardiovascular deaths 
in the vildagliptin group: from hepatic neoplasm, lung neoplasm, septic shock, and surgery for 
intestinal obstruction due to peritoneal adhesions. 
  
 
  
  
 
Figure 1: Study timeline  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2: Flow chart of participants 
 
 
 
 
  
 Figure 3. Change from baseline in left ventricular ejection fraction (primary endpoint) 
and other echocardiographic measures 
 
 
 
A. Change in LVEF (%). Difference in adjusted mean change 0.62 (95% CI: -2.21, 3.44; 
P=0.667)*. 
*Meets criteria for non-inferiority to comparator as the lower limit of the two sided 95% CI for 
the difference in mean change in LVEF is greater than -3.5%. Primary analysis is based on Per 
Protocol. B. Change in LVEDV (mL). Difference in adjusted mean change 17.06 (95% CI: 
4.62, 29.51; P=0.007). Full analysis set. C. Change in LVESV. Difference in adjusted mean 
change 9.44 (95% CI: -0.49, 19.38; P=0.062). Full analysis set.  D. Change in LVSV. 
Difference in adjusted mean change 9.00 (95% CI: 3.38, 14.62; P=0.002). Full analysis set. 
 
 
